|
|
|
| Clinical application of Recombinant Human Prourokinase combined with Tirofiban in PCI of ASTEMI patients with high thrombus burden |
| LUO Jiangbin FENG Xuxia CHEN Qijing WANG Tiansong HE Ximin |
| Department of Internal Medicine-Cardiovascular, Sanya People′s Hospital, Hainan Province, Sanya 572000, China |
|
|
|
Abstract Objective To investigate the clinical application of Recombinant Human Prourokinase (rhPro-UK) combined with Tirofiban in percutaneous coronary intervention (PCI) of patients with high thrombus burden and acute ST-segment elevation myocardial infarction (ASTEMI). Methods A total of 93 patients with high thrombus burden ASTEMI who underwent PCI at the Sanya People′s Hospital from June 2017 to May 2018 were enrolled. The patients were divided into observation group (47 cases) and control group (46 cases) according to the random number table method. The patients in both groups were given conventional PCI treatment. The control group was slowly injected with Tirofiban at the distal end of the coronary artery by aspiration catheter, while the observation group was treated with rhPro-UK on the basis of the control group. Cardiac function indicators, blood flow related indicators, the incidence of major adverse cardiovascular events (MACE) and adverse reactions were compared between the two groups before and after 2 weeks of treatment. Results Compared with before treatment, the left ventricular ejection fraction in the two groups was significantly increased after treatment, while the left ventricular end-diastolic diameter and left ventricular end-systolic diameter were significantly lower, and the differences were statistically significant (P ＜ 0.05). The proportion of thrombolysis in myocardial infarction (TIMI) in blood flow grade 3 and myocardial perfusion grade 3 in the observation group after treatment were significantly higher than those in the control group, while the corrected TIMI blood flow frame count was significantly lower than the control group, and the differences were statistically significant (P ＜ 0.05). There were no significant differences in the incidence of MACE and adverse reactions between the observation group and the control group, and the differences were not statistically significant (P ＞ 0.05). Conclusion rhPro-UK combined with Tirofiban in ASTEMI patients with high thrombus burden who underwent PCI has better curative effect and higher safety of prognosis. It has a good effect on the heart function and blood flow of patients, and it is worthy of clinical promotion.
|
|
|
|
|
|
[1] 付宝.溶栓后PCI与直接PCI治疗急性ST段抬高型心肌梗死的效果比较[J].中国合理用药探索，2018，15（3）：34-36.
[2] 刘志坚，冯冀，刘志辉，等.溶栓后PCI与pPCI治疗急性ST段抬高型心肌梗死的临床效果比较[J].基层医学论坛，2018，22（4）：520-522.
[3] 耿宏旭.急性ST段抬高型心肌梗死PCI术中冠状动脉内注射替罗非班对改善心肌灌注的临床研究[J].中国实用医刊，2018，45（9）：68-70.
[4] 韩梅，张驰，冯珺，等.重组人尿激酶原对老年性ST段抬高型心肌梗死患者近期心血管事件影响分析[J].中国心血管病研究，2018，16（5）：411-415.
[5] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志，2010，8（38）：675-687.
[6] Li H，Fu DG，Liu FY，et al. Evaluation of related factors，prediction and treatment drugs of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction after direct PCI [J]. Exp Ther Med，2018，15（4）：3940-3946.
[7] 刘晓健，顾顺忠.重组人尿激酶原治疗急性ST段抬高心肌梗死患者的疗效和安全性[J].安徽医学，2017，38（10）：1324-1327.
[8] 施巍.美托洛尔对急性ST段抬高型心肌梗死患者自主神经失衡的影响[J].中国药业，2015，24（22）：46-48.
[9] 张楠.替罗非班在急性ST段抬高型心肌梗死行PCI术患者中应用的最佳时机[J].中国医药导报，2018，15（8）：124-128.
[10] 张伯亨，张亚静，岳博成，等.尿激酶原联合血栓抽吸对高血栓负荷的STEMI患者的疗效观察[J].医学研究杂志，2018，47（5）：179-182.
[11] 方小赛.血栓抽吸导管与替罗非班联合治疗老年急性ST段抬高型心肌梗死的疗效及不良事件分析[J].基层医学论坛，2018，22（4）：490-491.
[12] 郝清卿，王立立，安少波，等.重组尿激酶原联合替罗非班在急性心肌梗死介入治疗中的作用[J].中国临床药理学杂志，2017，33（21）：2098-2100.
[13] 张蕊.ST段抬高型急性心肌梗死患者溶栓治疗中常规剂量替罗非班联合半剂量瑞替普酶的应用效果分析[J].中国实用医药，2018，13（12）：99-101.
[14] 郑望，邓兵，沈琳，等.重组人尿激酶原联合替罗非班在高血栓负荷急性 ST 段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗中的应用效果[J].实用心脑肺血管病杂志，2018，26（5）：91-92.
[15] 隆海文，谢迎春，甘剑挺，等.老年ST段抬高型急性心肌梗死转运PCI应用替罗非班的临床观察[J].心脑血管病防治，2018，18（1）：54-56.
[16] 巩贵宏，焦洁，杨建涛，等.复方丹参滴丸联合重组人尿激酶原治疗急性ST段抬高型心肌梗死的临床研究[J].现代药物与临床，2018，33（6）：1376-1379.
[17] 郭宏，孙牧，王安杏，等.替罗非班在急性ST段抬高型心肌梗死患者PCI术前治疗中的应用效果[J].中国医药导报，2017，14（9）：146-149.
[18] Zhao L，Zhao Z，Chen X，et al. Safety and efficacy of prourokinase injection in patients with ST-elevation myocardial infarction：phase Ⅳ clinical trials of the prourokinase phase study [J]. Heart Vessels，2018，33（5）：507-512.
[19] Tatlisu MA，Kaya A，Keskin M，et al. The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban [J]. Coron Artery Dis，2016，27（7）：543-550.
[20] 朱利娟.注射用重组人尿激酶原治疗急性ST段抬高型心肌梗死的疗效和安全性及影响因素分析[J].中西医结合心血管病电子杂志，2017，5（26）：60-62.
[21] 郭佳茹，郭寿贵.替罗非班联合瑞替普酶溶栓对老年ST段抬高型心肌梗死患者心功能指标变化、血清因子水平的影响[J].中国医药导报，2017，14（14）：119-122. |
|
|
|
